FDA wants another Riquent trial

La Jolla Pharmaceuticals (LJPC) received an approvable letter from FDA for lupus therapeutic Riquent abetimus in which the agency requested another clinical trial. According to LJPC, the FDA letter said the company's ongoing Phase IV trial of the compound could satisfy the new trial requirement. The Phase IV study is enrolling 500-600 patients. When LJPC started the trial in August, it said the study likely would take several years to complete. ...